

Expanded Access Policy

Sometimes called “compassionate use”, expanded access is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.

Kiromic BioPharma is committed to developing safe and effective therapies in the field of solid tumors and making them available to patients as quickly as possible. However, at this stage in development, *Kiromic BioPharma* is currently not able to make its investigational KB-GDT-01 (Deltacel™) therapy product available through an expanded access program, and access to *Kiromic BioPharma*’s investigational therapy is possible only through participation in clinical trials.

Learn more

Healthcare providers with questions should refer to <https://clinicaltrials.gov/> (ID NCT06069570) or contact Medical Information at MedInfo@kiromic.com.

Kiromic BioPharma reserves the right to revise this policy at any time under the 21st Century Cures Act.